Continuous intravenous infusion of TRH-T: Clinical, cardiovascular and endocrinological effects

R. Formisano, S. Ruggieri, R. Cerbo, F. Lucarelli, G. De Vuono, M. Parmegiani, A. Agnoli, A. Attanasio, A. Capria, C. G C Piccolo, E. Fabrizi, D. Cannata

Research output: Contribution to journalArticlepeer-review


Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one from Friedreich ataxia, were treated with a placebo i.v. infusion during the first day and with TRH-T i.v. infusion at a rate of 2 mg/h for 8 h daily (total daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) and EKG monitorings were performed during 3 days infusion. Blood samples were collected for endocrinological evaluations. The neurological evaluation after acute TRH-T treatment showed an objective improvement in 3 of the 8. We found significantly higher values of systolic (max. difference of 10.1 mm Hg) and diastolic (max. difference of 8.8 mmHg) BP than during placebo, beginning from the 5th h of the infusion (p <0.05). A trend in progressive increase of the heart rate (HR) reached statistical significance (p <0.01) at the 8th h of the second TRH-T infusion. The cardiovascular changes during the i.v. continuous TRH-T infusions were clinically irrelevant and never required the interruption of the treatment.

Original languageEnglish
Pages (from-to)514-518
Number of pages5
JournalActa Neurologica Scandinavica
Issue number6
Publication statusPublished - 1991


  • amyotrophic lateral sclerosis
  • cardiovascular effects
  • continuous intravenous infusion
  • TRH-T

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Continuous intravenous infusion of TRH-T: Clinical, cardiovascular and endocrinological effects'. Together they form a unique fingerprint.

Cite this